Form 8-K - Current report:
SEC Accession No. 0001558370-24-014522
Filing Date
2024-11-06
Accepted
2024-11-06 07:21:05
Documents
15
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20241106x8k.htm   iXBRL 8-K 40805
2 EX-99.1 acrs-20241106xex99d1.htm EX-99.1 196135
3 GRAPHIC acrs-20241106xex99d1001.jpg GRAPHIC 7805
  Complete submission text file 0001558370-24-014522.txt   380173

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20241106.xsd EX-101.SCH 3136
5 EX-101.LAB acrs-20241106_lab.xml EX-101.LAB 15917
6 EX-101.PRE acrs-20241106_pre.xml EX-101.PRE 10224
17 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20241106x8k_htm.xml XML 4840
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 241429232
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)